Electrical skin rejuvenation

Information

  • Patent Grant
  • 9278230
  • Patent Number
    9,278,230
  • Date Filed
    Monday, February 22, 2010
    14 years ago
  • Date Issued
    Tuesday, March 8, 2016
    8 years ago
Abstract
A method is provided for reducing a wrinkle on a skin surface (42). The method includes identifying a person having a skin surface (42) with a wrinkle and in response to identifying the person, positioning at respective sites on the skin surface (42) an array (44) of electrodes (60) coupled to an energy source (46). While the electrodes (60) are at the respective sites: during a first time period, applying energy from the energy source (46) to drive the electrodes (60) to apply radio frequency (RF) current at a first voltage, capable of ablating an epidermal layer of the skin; and during a second time period, applying energy from the energy source (46) to drive the electrodes (60) to apply current at a second voltage, lower than the first voltage. Other embodiments are also described.
Description
FIELD OF EMBODIMENTS OF THE INVENTION

Some embodiments of the present invention relate generally to skin rejuvenation, and particularly to methods and apparatus for wrinkle reduction.


BACKGROUND

Skin, the body's largest organ, is composed of multiple layers. The outer layer, epidermis, is divided into several sublayers; the outermost layer is termed stratum corneum epidermidis. The stratum corneum is generally a non-innervated cell layer consisting of mainly large, dead cells that lack nuclei. Beneath the epidermis, lies the dermis skin layer, which is tightly connected to the epidermis.


A major structural component of the skin is collagen, a fibrous protein, which contributes to skin strength and elasticity. As such, collagen formation and remodeling lead to changes in mechanical properties of the skin such as texture and resilience. Typically, collagen plays an important role in the regeneration of epidermal tissue in wounded skin. Collagen is produced during the wound healing process, thus increasing the tensile strength of a wound.


Collagen contraction, or thermal shrinkage of collagen, occurs by the dissociation of heat-sensitive bonds of the collagen molecule. Thermal denaturing of collagen results in a tightening effect of the skin. In contrast, age-related degradation of collagen leads to sagging of the skin and the formation of wrinkles. Many wrinkles appear on exposed areas of the skin, e.g., the face, the neck and the forearms. These visible effects of aging of the skin are disturbing to some individuals, and therefore methods for rejuvenation of maturing or damaged skin are of interest.


U.S. Pat. No. 6,461,354 to Olsen et al. describes systems and methods for selectively applying electrical energy to a target location on an external body surface, such as for skin tissue removal and/or collagen shrinkage in the epidermis or dermis, e.g., the removal of pigmentations, vascular lesions (e.g., leg veins), scars, tattoos, etc., and for other surgical procedures on the skin, such as tissue rejuvenation, cosmetic surgery, wrinkle removal, hair removal and/or transplant procedures. The described system and methods apply high frequency (RF) electrical energy to one or more electrode terminals adjacent an external body surface, such as the outer surface of the skin, to remove and/or modify the structure of tissue structures within the skin. Depending on the specific cosmetic procedure, the described system and methods may be used to: (1) volumetrically remove tissue or hair (i.e., ablate or effect molecular dissociation of the tissue structure); (2) separate a tissue layer from an underlying tissue layer so that the tissue layer can be removed; (3) shrink or contract collagen connective tissue; and/or (4) coagulate blood vessels underlying the surface of the skin.


U.S. Pat. No. 6,381,498 to Knowlton describes a method and apparatus that applies radiant energy through the skin to underlying collagen tissue, and is described as not substantially modifying melanocytes and other epithelial cells in the epidermis. A membrane is adapted to receive an electrolytic solution and become inflated to substantially conform to a contacting exterior surface of the membrane to a skin layer. The membrane includes a cooling lumen for receiving cooling fluid. One or more thermal electrodes positioned in the membrane transfers thermal energy to the electrolytic solution. The electrolytic solution and cooling fluid is described as creating a reverse thermal gradient from the skin surface to the underlying collagen tissue. A thermal power source is coupled to the thermal electrodes, and a source of electrolytic solution is coupled to the membrane.


US 2006/0036300 to Kreindel describes a method of lipolysis. The method comprises deforming a region of skin so that the region of skin protrudes from surrounding skin. One or more radio frequency (RF) electrodes are positioned on the protruding region of skin so as to generate an electrical current through adipose tissue in the protruding region of skin when a voltage is applied to the electrode or electrodes. A voltage is then applied to the electrode or electrodes so as to deliver sufficient RF energy to the protruding region of skin to damage subcutaneous adipose tissue. The described method may be used, for example, to achieve a reduction in body weight, cellulite reduction, loose skin reduction, wrinkle treatment, body surface tightening, skin tightening, and collagen remodeling.


U.S. Pat. No. 6,684,107 to Binder describes a system for reducing wrinkles on human skin that utilizes an electrode to conduct a microcurrent through the surface of the wrinkle into the underlying dermal layer. The electrode is moved in multiple passes along the length of the wrinkle, with the electrode in contact with the surface of the wrinkle while generating a periodically repeating microcurrent having a peak amplitude in the range of 10-40 microamps, a peak current density in the range of 10-50 microamps/cm.sup.2, and a frequency in the range of 5-15 Hz. The electrode device is described as self-contained in a battery-containing, cordless case from which a contact electrode protrudes. A hand-engaging second electrode on the surface of the case completes a conductive path through the user's body.


U.S. Pat. No. 6,148,232 to Avrahami describes a device for ablating the stratum corneum epidermidis of a subject, including a plurality of electrodes, which are applied to the subject's skin at respective points. A power source applies electrical energy between two or more of the plurality of electrodes, in order to cause ablation of the stratum corneum primarily in an area intermediate the respective points.


U.S. Pat. No. 6,611,706 to Avrahami describes a device for facilitating transdermal passage of a substance through skin on the body of a subject. The device preferably includes an electrode and a control unit. In a preferred embodiment, the control unit is adapted to drive the electrode to apply to the skin a current capable of ablating stratum corneum epidermidis of the skin, so as to facilitate transdermal passage of the substance. The control unit detects generation of at least one spark responsive to application of the current, and modifies a parameter of the current responsive to detecting the generation of the at least one spark.


U.S. Pat. No. 6,708,060 to Avrahami describes a device for treating skin on the body of a subject. The device includes a plurality of electrodes, which are adapted to be placed in contact with the skin and then moved across the skin while maintaining electrical contact with the skin. The device additionally includes a power source, which is adapted to apply a current between two or more of the plurality of electrodes at the same time as the electrodes are being moved across the skin.


Reliant Technologies (California, US) distributes the Fraxel family of cosmetic products, which includes three fractional lasers that produce two non-ablative treatments and one ablative treatment.


The following patent and patent applications may be of interest:


US 2005/0003518 to Avrahami et al.


US 2005/0119605 to Sohn


US 2005/0187497 to Nguyen


US 2006/0089688 to Panescu


US 2007/0270732 to Levine


US 2007/0287949 to Levine et al.


US 2007/0292445 to Levine


US 2008/0114281 to Birchall et al.


U.S. Pat. No. 5,569,242 to Lax et al.


U.S. Pat. No. 5,746,746 to Garito et al


U.S. Pat. No. 6,026,327 to Dervieux


U.S. Pat. No. 6,597,946 to Avrahami et al.


U.S. Pat. No. 6,711,435 to Avrahami


U.S. Pat. No. 7,123,957 to Avrahami


U.S. Pat. No. 7,335,377 to Stern


U.S. Pat. No. 7,395,111 to Levine et al.

















US 2002/0068930



US 2002/0087155



US 2002/0095152



US 2002/0128641



US 2002/0193789



US 2003/0009164



US 2003/0097126



US 2003/0097129



US 2003/0097162



US 2003/0120269



US 2003/0130655



US 2003/0158545



US 2003/0163178



US 2003/0187488



US 2003/0212396



US 2004/0215184



US 2005/0107832



US 2005/0256519



US 2006/0036300



US 2006/0047281



US 2006/0058727



US 2006/0173518



US 2007/0010811



US 2007/0032840



U.S. Pat. No. 5,660,836



U.S. Pat. No. 5,681,282



U.S. Pat. No. 5,697,909



U.S. Pat. No. 5,746,746



U.S. Pat. No. 5,755,753



U.S. Pat. No. 5,766,153



U.S. Pat. No. 5,843,019



U.S. Pat. No. 5,888,198



U.S. Pat. No. 5,919,219



U.S. Pat. No. 5,948,011



U.S. Pat. No. 6,119,038



U.S. Pat. No. 6,179,836



U.S. Pat. No. 6,235,020



U.S. Pat. No. 6,241,753



U.S. Pat. No. 6,264,652



U.S. Pat. No. 6,355,032



U.S. Pat. No. 6,377,855



U.S. Pat. No. 6,381,498



U.S. Pat. No. 6,387,380



U.S. Pat. No. 6,405,090



U.S. Pat. No. 6,413,255



U.S. Pat. No. 6,432,103



U.S. Pat. No. 6,461,354



U.S. Pat. No. 6,468,270



U.S. Pat. No. 6,482,201



U.S. Pat. No. 6,544,261



U.S. Pat. No. 6,557,559



U.S. Pat. No. 6,575,968



U.S. Pat. No. 6,623,454



U.S. Pat. No. 6,632,193



U.S. Pat. No. 6,662,054



U.S. Pat. No. 6,684,107



U.S. Pat. No. 6,766,202



U.S. Pat. No. 6,832,996



U.S. Pat. No. 6,837,887



U.S. Pat. No. 6,837,888



U.S. Pat. No. 6,896,672



U.S. Pat. No. 6,974,453



U.S. Pat. No. 7,006,874



U.S. Pat. No. 7,010,343



U.S. Pat. No. 7,022,121



U.S. Pat. No. 7,083,580



U.S. Pat. No. 7,115,123



U.S. Pat. No. 7,141,049



U.S. Pat. No. 7,189,230



U.S. Pat. No. 7,201,750



WO 9426228



WO 9632051



WO 9634568



WO 9803220



WO 9917690



WO 9920185



WO 9920213



WO 9926546



WO 0009053



WO 0053113



WO 0056229



WO 0062685



WO 0062698



WO 0195819



WO 0160273



WO 02102255



WO 03005882



WO 03028540



WO 03043696



WO 03065915



WO 03079916



WO 03086217



WO 04086943



WO 04089185



WO 04105861



WO 06054150



WO 06080012



WO 06109334










SUMMARY

In some applications of the present invention, an apparatus and a method for reducing a wrinkle on a skin surface is provided. An array of electrodes coupled to an energy source is positioned on the wrinkle. The electrodes remain at the same sites on the skin surface for at least two successive periods of time. During the first period of time, energy from the energy source is applied to drive the electrodes to apply radio frequency (RF) current at a first voltage. The current applied at the first voltage is capable of locally ablating the epidermal tissue (and typically superficial dermal tissue) in close proximity to the electrodes. Ablation of the epidermal tissue (and typically superficial dermal tissue) by the applied RF current generates micro-channels through the epidermis (and typically superficial dermis). The formation of the micro-channels induces natural body fluid to enter the micro-channels. Whereas during ablation the resistance between electrodes increases, the resistance subsequently decreases when body fluid enters the micro-channels. During the subsequent, second time period, energy from the energy source is applied to drive the electrodes to apply current at a second voltage, lower than the first voltage. The current applied at the second voltage is sufficient to continuously heat the fluid within the micro-channels and underlying tissue, but generally does not cause further ablation.


The inventors hypothesize that the ablation of epidermal tissue (and typically superficial dermal tissue) with subsequent heating of underlying tissue leads to collagen regeneration and remodeling, resulting in skin rejuvenation. The first phase of RF application ablates micro-channels in the epidermal layer (and typically superficial dermal layer) of the skin in close proximity to the electrodes, as described hereinabove. The ablation of the micro-channels triggers the initiation of a wound healing process in the skin, in which production of collagen is induced. The second phase of lower voltage, non-ablating current application heats the natural body fluid present within the micro-channels, leading to the controlled heating of underlying collagen tissue, causing thermally-mediated collagen contraction. The effect of the combined ablation and heating method of these applications of the present invention is skin tightening and wrinkle reduction. It is noted that although a wound healing process is initiated, ablation of micro-channels into the epidermis (and typically superficial dermis), as provided herein, generally does not cause pain to a subject.


The term “micro-channel,” as used in the context of the present patent application and in the claims, refers to a pathway generally extending from the surface of the skin through at least the epidermis. Such micro-channels are formed due to local power dissipation leading to ablation of the epidermis (and typically superficial dermis) when an electric field of sufficient magnitude is applied to a small area of the skin, in contact with the electrodes, for a sufficient period of time.


There is therefore provided, in accordance with some applications of the invention, a method for reducing a wrinkle on a skin surface, including:


identifying a person having a skin surface with a wrinkle;


in response to identifying the person, positioning at respective sites on the skin surface an array of electrodes coupled to an energy source; and


while the electrodes are at the respective sites:

    • during a first time period, applying energy from the energy source to drive the electrodes to apply radio frequency (RF) current at a first voltage, capable of ablating an epidermal layer of the skin; and
    • during a second time period, applying energy from the energy source to drive the electrodes to apply current at a second voltage, lower than the first voltage.


In some applications, applying energy during the first time period includes applying the energy for 1-20 ms.


In some applications, applying energy during the second time period includes applying the energy for at least 1 second.


In some applications, applying energy during the second time period includes initiating applying the energy through a given electrode during the second time period at least 10 ms after application of energy through the given electrode during the first time period.


In some applications, applying energy during the second time period includes applying only non-ablating energy during the second time period.


In some applications, applying energy during the first time period includes setting a voltage of the energy applied during the first time period to be 150-350 V base-to-peak.


In some applications, applying energy during the second time period includes setting a voltage of the energy applied during the second time period to be 10-200 V base-to-peak.


In some applications, applying energy during the second time period includes setting a voltage of the energy applied during the second time period to be 10-100 V base-to-peak.


In some applications, applying energy during the first time period includes setting a frequency of the energy applied during the first time period to be 50-500 kHz.


In some applications, applying energy during the second time period includes setting a frequency of the energy applied during the second time period to be 50-500 kHz.


In some applications, applying energy during the first time period includes ablating micro-channels in the epidermal layer.


In some applications, applying energy during the second time period includes initiating application of the energy during the second time period subsequently to filling of the micro-channels with body fluid.


There is further provided, in accordance with some applications of the present invention, apparatus for reducing a wrinkle on a skin surface, including:


an array of electrodes configured to be placed on the skin surface; and


an energy source coupled to the array of electrodes and configured to apply energy to drive the electrodes to apply ablating current at a first voltage during a first period of time and to apply non-ablating current at a second voltage, lower than the first voltage, during a second period of time.


In some applications, the energy source is configured to apply energy for 1-20 ms during the first time period.


In some applications, the energy source is configured to apply energy for at least 1 second during the second time period.


In some applications, the energy source is configured to apply energy, during the second time period, through a given electrode at least 10 ms after application of energy through the given electrode during the first time period.


In some applications, the energy source is configured to convey to the electrodes 150-350 V base-to-peak during the first period of time.


In some applications, the energy source is configured to convey to the electrodes 10-200 V base-to-peak during the second period of time.


In some applications, the energy source is configured to convey to the electrodes 10-100 V base-to-peak during the second period of time.


In some applications, the energy source is configured to apply energy at a frequency of 50-500 kHz during the first time period.


In some applications, the energy source is configured to apply energy at a frequency of 50-500 kHz during the second time period.


In some applications, the array of electrodes includes at least 10 electrodes.


In some applications, the array of electrodes includes at least 50 electrodes.


In some applications, the electrodes of the array are arranged in a 2×n rectangular array.


In some applications, the array of electrodes includes electrodes, each electrode 60-80 um in diameter.


In some applications, the array of electrodes includes electrodes, each electrode 50-400 um in length.


In some applications, the array of electrodes includes electrodes, each electrode 100-250 um in length.


In some applications, the array of electrodes includes electrodes generally evenly spaced in the array, the distance between adjacent electrodes being 0.5-1.5 mm.


In some applications, the energy source is configured to apply energy capable of ablating micro-channels in an epidermal layer of the skin during the first period of time.


In some applications, the energy source is configured to initiate application of energy subsequently to filling of the micro-channels with body fluid, during the second period of time.


There is yet further provided, in accordance with some applications of the present invention, apparatus for reducing a wrinkle on a skin surface, including:


an array of at least 10 electrodes, each electrode at least 150 um in length, configured to be placed on the skin surface; and


an energy source coupled to the array of electrodes and configured to apply energy to drive the electrodes to apply 50-500 kHz current capable of ablating an epidermis layer of the skin.


In some applications, the array includes at least 100 electrodes.


In some applications, the electrodes of the array are arranged in a 2×n rectangular array.


In some applications, the electrodes of the array are arranged in an m×n rectangular array, n being at least four times greater than in.


In some applications, each electrode is 60-80 um in diameter.


In some applications, the array of electrodes includes electrodes generally evenly spaced in the array, the distance between adjacent electrodes being 0.5-1.5 mm.


There is also provided, in accordance with some applications of the present invention, a method for reducing a wrinkle on a skin surface, including:


identifying a person having a skin surface with a wrinkle;


in response to identifying the person, positioning at respective sites on the skin surface at least 10 electrodes coupled to an energy source; and


ablating an epidermal layer of the skin by applying energy from the energy source to drive the electrodes to apply 50-500 kHz current.


The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a schematic illustration of apparatus for reducing wrinkles positioned on a skin surface containing a wrinkle, in accordance with some applications of the present invention;



FIG. 1B is a schematic illustration of an array of electrodes positioned in contact with the skin surface, and respective ablated sites on the subject's skin, in accordance with some applications of the present invention;



FIG. 1C is a schematic illustration of the array of electrodes positioned in contact with the skin surface, during a subsequent heating step, in accordance with some applications of the present invention; and



FIG. 2 is a graph representing an average change in wrinkle depth of eight subjects following application of RF energy, in accordance with some applications of the present invention.





DETAILED DESCRIPTION OF THE EMBODIMENTS


FIG. 1A is a schematic illustration of apparatus 40 for reducing wrinkles, during use by a subject, in accordance with some applications of the present invention. Apparatus 40 is positioned on skin surface 42 containing a wrinkle (e.g., on the face, the forehead or the neck). Apparatus 40 typically comprises an energy source 46, a reusable control unit 48, and a typically disposable sterile array 44 of electrodes 60. When positioned on skin surface 42, array 44 of electrodes 60 is in direct contact with the stratum corneum layer of the skin.


Array 44 is typically 0.5-2 cm2 (e.g., 0.96 cm2), and typically comprises 10-1000 electrodes, e.g., 50-250 electrodes. In all experiments described herein, array 44 comprises 144 electrodes. For some applications (e.g., those used in the experiments described herein), array 44 is arranged as an n×n array, i.e., a square array of electrodes. For other applications, e.g., where it is desired to primarily apply energy in a series of applications along the length of a wrinkle (and to a lesser extent to surrounding tissue), a long, thin, rectangular array is utilized, e.g., an m×n array, where m is typically 2, 3, 4, 5, or 6, and n is typically between 10 and 30, or between 30 and 100. For example, the array may be a 2×10 array. For these applications, n is typically at least four times greater than m (e.g., at least eight times greater than m).


Each electrode 60 is typically 60 um-80 um in diameter and 50 um-400 um in length, e.g., 100-250 um in length, in order to reach the epidermal tissue (and typically superficial dermal tissue). Array 44 is typically snapped on to a housing of apparatus 40 prior to use and ejected after use.


The distance between adjacent electrodes is typically 0.5-1.5 mm, and the electrodes are typically generally evenly spaced in the array. With an array of small diameter electrodes, which are typically generally evenly-spaced electrodes, and with no particular effort by the operator of the apparatus, generally uniform heating of the skin under array 44 is obtained, particularly during the second time period of energy application (described hereinbelow).


Control unit 48 (FIGS. 1B-C) comprises electronic and software components configured to drive energy source 46 to initiate or discontinue energy application to electrodes 60.


Reference is made to FIG. 1B, which is a schematic illustration of array 44 positioned in contact with skin surface 42, in accordance with some applications of the present invention. In some applications of the present invention, array 44 remains at the same sites on skin surface 42 for at least two periods of time. Energy source 46 applies energy to drive array 44 of electrodes 60 to apply RF energy to skin surface 42. Energy source 46 is configured to apply energy to drive the electrodes to apply current at different voltages during the two time periods. During the first time period, represented in FIG. 1B, energy source 46 applies energy to drive array 44 of electrodes to apply a 1-20 ms burst of RF current at 200-350 V base-to-peak (i.e., 400-700 V peak-to-peak) and 50-500 kHz (e.g., 100 kHz) to the epidermis (and typically superficial dermis) of skin surface 42.


When apparatus 40 drives a sufficient amount of energy through the epidermis (and typically superficial dermis), during the first time period, these skin layers are ablated by the energy dissipating through them. Each individual electrode typically applies this current at a current of 1-20 mA. Typically, 2-12 electrodes (e.g., four electrodes) are simultaneously driven to drive the RF current into the skin, resulting in a correspondingly higher total instantaneous current (e.g., 4-80 mA). The remaining electrodes in array 44 typically serve as return electrodes, and due to their greater number, the return electrodes produce substantially lower current densities in the skin. This ablation creates micro-channels 50, i.e. physical pores in the epidermis (and typically superficial dermis). Micro-channels 50 are accurately reproducible as well as typically small and not visible to a naked eye. Depending on local skin conditions and the current protocol used, the micro-channels are typically 40-100 um in diameter, and 50-400 um (e.g., 30-200 um) in depth.


When each micro-channel 50 has formed in response to current flow by the electrodes, it remains an empty pore until body fluid permeates it. Typically, a given micro-channel 50 is filled by natural body fluid within approximately 30 ms after formation of the micro-channel has occurred. Ablation of micro-channels 50 generally does not cause pain or substantial trauma to skin layers underlying the superficial dermis. Although any wound caused by ablation of the skin is minimal, a natural process of wound healing is induced by formation of micro-channels 50. Production of collagen, which occurs naturally as part of wound healing, leads to a smoother, elastic skin appearance.


Reference is made to FIG. 1C, which is a schematic illustration of array 44 positioned in contact with skin surface 42, without having been moved from the site where ablation was produced, in accordance with some applications of the present invention. As described hereinabove, energy source 46 drives electrodes 60 to apply current at different voltages during two lime periods. FIG. 1C represents the second time period, in which energy source 46 applies energy to drive the electrodes to apply current at a lower voltage than was applied during the first time period. Although the current applied by the electrodes during the second time period can be AC or DC and can have a range of parameters that would induce heating, the current typically has a frequency of 50-500 kHz (e.g., 100 kHz), and may, for example, have the same frequency as that applied during the first time period.


In accordance with a protocol for the first and second time periods, ablation through a given electrode, or small group of electrodes (e.g., four electrodes) is performed during the first time period for that subset of one or more electrodes. Then, another subset of one or more electrodes ablates, during a first time period for that subset of electrodes. This process is repeated until typically substantially all of the electrodes have applied ablating energy to the skin. Subsequently, in the second time period, current is applied at a lower voltage through all of the electrodes, in order to induce uniform heating across the area of skin under array 44. The current driven by energy source 46 during the second time period is typically (but not necessarily) less than 100 mA, and is usually about 10-50 mA. The current driven through any one electrode during the second time period is typically 0.1-1 mA. For some applications, e.g., when array 44 has a smaller number of electrodes, or not all of the electrodes are applying current simultaneously, the current driven through any one electrode may be 1-10 mA.


In some applications, the second period of time is initiated on an electrode-by-electrode basis or a subset-by-subset basis, typically at least 10 ms from the termination of the first time period at any given electrode. For example, each electrode, or small subset of electrodes, may have its own first and second time periods, before another electrode or subset of electrodes has its first time period. For some applications, a first subset of one or more of the electrodes are applying energy in accordance with a first time period protocol, while another subset of one or more electrodes are applying energy in accordance with a second time period protocol.


Typically, in at least one operational mode of apparatus 40, the number n2 of electrodes applying non-ablating energy during any given second time period is higher than the number n1 of electrodes that apply ablating energy during any given first time period. For example, n2 is typically at least 3 or 10 times higher than n1.


The duration of current application during the second time period is typically 1-30 seconds, or 30-200 seconds. The energy applied during the second time period is non-ablating, but typically sufficient to heat body fluid 54 present within micro-channels 50 to a temperature suitable for inducing ongoing changes to collagen. In an experiment, an array 44 of 144 electrodes, 70 um in length, applied 100 kHz current to a volunteer during the first time period for 7 ms at 200 V base-to-peak, in order to ablate at least a portion of the epidermis, and produce micro-channels. During the second time period, array 44 was maintained at the same place as during the first time period, and applied 100 kHz current for approximately 20 seconds, at 80 V base-to-peak. The volunteer reported no unpleasant sensation due to current application during either period. In other experiments described hereinbelow, similar first-time-period protocols were used, without a second time period, and produced measurable wrinkle reduction. In this first and second time period experiment, no measurements were made of wrinkle reduction.


Heating body fluid 54 within micro-channels 50 leads to the controlled heating of underlying collagen tissue, causing thermally-mediated collagen contraction. Thermally-mediated collagen contraction, or shrinkage, typically results in a tightening effect of the skin. Skin tightening and wrinkle reduction are the synergistic effect of the ablation and lower-temperature heating methods of these embodiments of the present invention.


Typically, the use of apparatus 40 results in skin rejuvenation and wrinkle reduction.


In experiments described hereinbelow, performed by the inventors using a version of apparatus 40 that only ablates and does not utilize heating during the second time period, ablation of micro-channels 50 was found to trigger a wound healing process in the skin, in which collagen formation is naturally induced.


The following examples are provided in order to illustrate the effects of embodiments of the present invention.



FIG. 2 is a graph representing the average changes in wrinkle depth in response to treatment by the method and apparatus for electrical skin rejuvenation, in accordance with some applications of the present invention. In this set of experiments, wrinkle depth on a subject's forehead was determined by silicone imprint analysis of the wrinkles examined. Skin surfaces containing wrinkles from eight subjects were subjected to two treatments with apparatus 40 separated by one month, and measurement were taken prior to the first treatment, and over the course of the next two months. Each treatment comprised applying RF energy through 200 um long electrodes in an array 44 of 144 electrodes, at a voltage of 330 V and a frequency of 100 kHz. The energy was applied to the skin surface in one burst of energy, for a duration of 9 ms. Subsequently, array 44 was removed from the skin and then replaced, within the abilities of the experimenter, on essentially the same location (but not the identical location), such that effectively the same area of skin was covered by the array, even though the electrodes were at an uncontrolled location with respect to the previously-generated micro-channels. Current was applied again, using the same protocol. Subsequently, array 44 was again removed and replaced, and current was applied a third time, again using the same protocol.


As shown in FIG. 2, there is a clear change over time in wrinkle depth in treated skin surfaces over eight weeks. All subjects responded to the treatment and demonstrated gradual improvement and a decrease in wrinkle depth during the course of the study. After two weeks, four weeks and eight weeks the average improvement was 11.06%, 18.25% and 25.3% respectively.


Table I is a table representing skin analysis of eight subjects following treatment by the method and apparatus described herein for electrical skin rejuvenation, in accordance with some applications of the present invention, using the protocol described hereinabove with reference to FIG. 2.













TABLE I









Epidermis Cell





Proliferation
Collagen
Elastin














Subject
Subject

Non-
Fiber
Fiber


Group
Number
Age
Treated
treated
Content
Content





A
1
35
23
19
no change
no change


A
2
40
14
16
no change
no change


A
3
41
31
19
no change
no change


A
4
42
12
30
no change
increase








in fiber








content


B
5
47
60
37
increase
increase







in fiber
in fiber







content
content


B
6
47
25
18
small
increase







increase
in fiber







in fiber
content







content


B
7
50
20
13
increase
no change







in fiber







content


B
8
51
56
16
increase
increase







in fiber
in fiber







content
content









In this set of experiments, forearm skin biopsy samples were taken from treated and non-treated skin surfaces of eight subjects. The subjects were divided into two age groups. The younger age group (35-42 y) was designated group A, and the older age group (47-51 y) was designated group B. The skin samples were analyzed for collagen and elastin content, as determined by collagen and elastin staining; and epidermal cell proliferation, as determined by a specific marker for proliferating cells (Ki67). As shown in Table I, all subjects in group B showed increased collagen fiber content and increased skin cell proliferation in response to treatment by the method and apparatus for skin rejuvenation, in accordance with some applications of the present invention. Additionally, 75% of the subjects in group B, showed an increase in elastin fiber content. In contrast, the collagen fiber content of subjects in group A was not altered by the treatment. In addition, only 25% of the subjects in group A showed increased elastin content and 50% exhibited increased cell proliferation in response to treatment. Separate results (not shown) demonstrated that pain, erythema, and edema produced during the study were acceptable in each of the test subjects.


Trans Epidermal Water Loss (TEWL) was analyzed following treatment of skin surfaces of foreheads and forearms of subjects. The skin surfaces were treated with the method and apparatus for skin rejuvenation, in accordance with some applications of the present invention. Analysis of the results of the studies preformed on the forearm site show that following the first treatment, TEWL value was significantly higher than the TEWL value measured prior to initiation of treatment (as measured with a VapoMeter (Delfin Technologies, Ltd.) (p=0.012) and according to the Wilcoxon signed-ranks test. TEWL values remained significantly elevated for 48 hours to one week following treatment. (Similar results were obtained for the forehead site.)


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. A method for reducing a wrinkle on a skin surface, comprising: identifying a skin surface with a wrinkle;positioning at respective sites on the skin surface an array of electrodes communicatively coupled to an energy source; andwhile the electrodes are positioned at the respective sites: during a first time period, applying energy from the energy source to drive the electrodes to apply a radio frequency (RF) current at a first voltage sufficient to ablate micro-channels in the epidermal layer of the skin and, at least partially, ablate collagenous dermal tissue, the micro-channels accessing the ablated collagenous dermal tissue; andduring a second time period, applying energy from the energy source to drive the electrodes to apply a current at a second voltage lower than the first voltage;wherein applying energy during the second time period comprises initiating application of the energy: at least 10 ms after the first time period application of energy; andsubsequent to filling of the micro-channels with body fluid.
  • 2. The method according to claim 1, wherein applying energy during the first time period comprises applying the energy for 1-20 ms.
  • 3. The method according to claim 1, wherein applying energy during the second time period comprises applying the energy for at least 1 second.
  • 4. The method according to claim 1, wherein applying energy during the second time period comprises applying only non-ablating energy during the second time period.
  • 5. The method according to claim 1, wherein applying energy during the first time period comprises setting a voltage of the energy applied during the first time period to be 150-350 V base-to-peak.
  • 6. The method according to claim 1, wherein applying energy during the second time period comprises setting a voltage of the energy applied during the second time period to be 10-200 V base-to-peak.
  • 7. The method according to claim 1, wherein applying energy during the second time period comprises setting a voltage of the energy applied during the second time period to be 10-100 V base-to-peak.
  • 8. The method according to claim 1, wherein applying energy during the first time period comprises setting a frequency of the energy applied during the first time period to be 50-500 kHz.
  • 9. The method according to claim 1, wherein applying energy during the second time period comprises setting a frequency of the energy applied during the second time period to be 50-500 kHz.
  • 10. A method for reducing a wrinkle on a skin surface, comprising: identifying a skin surface with a wrinkle;positioning at respective sites on the skin surface an array of electrodes communicatively coupled to an energy source; andwhile the electrodes are positioned at the respective sites: during a first time period, applying energy from the energy source to drive the electrodes to apply a radio frequency (RF) current at a first voltage for 1-20 ms, the first voltage sufficient to ablate micro-channels in the epidermal layer of the skin and, at least partially, ablate collagenous dermal tissue, the micro-channels accessing the ablated collagenous dermal tissue; andduring a second time period, applying energy from the energy source to drive the electrodes to apply a current at a second voltage lower than the first voltage for at least 1 second;wherein applying energy during the second time period comprises initiating application of the energy: at least 10-99 ms after the first time period application of energy; andsubsequent to filling of the micro-channels with body fluid.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application claims the priority of U.S. Provisional Application 61/208,621 to Levin, entitled, “Electrical skin rejuvenation,” filed Feb. 25, 2009, which is incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/IL2010/000149 2/22/2010 WO 00 10/19/2011
Publishing Document Publishing Date Country Kind
WO2010/097790 9/2/2010 WO A
US Referenced Citations (385)
Number Name Date Kind
1430354 Burdick Sep 1922 A
2088780 Follese Aug 1937 A
2183726 Sommer et al. Feb 1939 A
2231095 Sommer et al. Feb 1941 A
2727132 Hills Dec 1955 A
2824308 Duncan Feb 1958 A
2888927 Fozard Jun 1959 A
3088205 Ellis May 1963 A
D196532 Facci Oct 1963 S
4016886 Doss et al. Apr 1977 A
4174713 Mehl Nov 1979 A
4182329 Smit et al. Jan 1980 A
4185632 Shaw Jan 1980 A
4200104 Harris Apr 1980 A
4211230 Woltosz Jul 1980 A
4228931 Ruscitti et al. Oct 1980 A
4321926 Roge Mar 1982 A
D269294 Rakocy et al. Jun 1983 S
D271015 Geraets Oct 1983 S
D271199 Geraets Nov 1983 S
4444190 Mutzhas Apr 1984 A
D274462 Rakocy et al. Jun 1984 S
4532924 Auth et al. Aug 1985 A
4550728 Runyon et al. Nov 1985 A
4553936 Wang Nov 1985 A
4566454 Mehl et al. Jan 1986 A
4686986 Fenyo et al. Aug 1987 A
4753958 Weinstein et al. Jun 1988 A
4784135 Blum et al. Nov 1988 A
4844063 Clark Jul 1989 A
4867682 Hammesfahr et al. Sep 1989 A
4869584 Dion Sep 1989 A
5016999 Williams May 1991 A
5071418 Rosenbaum Dec 1991 A
5125928 Parins et al. Jun 1992 A
5169384 Bosniak et al. Dec 1992 A
5286479 Garlich et al. Feb 1994 A
5316473 Hare May 1994 A
5319363 Welch et al. Jun 1994 A
5348554 Imran et al. Sep 1994 A
5353798 Sieben Oct 1994 A
5383874 Jackson et al. Jan 1995 A
5402697 Brooks Apr 1995 A
5406340 Hoff Apr 1995 A
5418130 Platz et al. May 1995 A
5449378 Schouenborg Sep 1995 A
5487662 Kipke et al. Jan 1996 A
5509916 Taylor Apr 1996 A
5520684 Imran May 1996 A
5521392 Kennedy et al. May 1996 A
5564851 Connely et al. Oct 1996 A
5582476 Hansen Dec 1996 A
5611793 Wilson et al. Mar 1997 A
5628771 Mizukawa et al. May 1997 A
5642997 Gregg et al. Jul 1997 A
5658148 Neuberger et al. Aug 1997 A
5674267 Mir et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5683380 Eckhouse et al. Nov 1997 A
5693052 Weaver Dec 1997 A
5698866 Doiron et al. Dec 1997 A
5704935 Pahl et al. Jan 1998 A
5707403 Grove et al. Jan 1998 A
5718702 Edwards Feb 1998 A
5722411 Suzuki et al. Mar 1998 A
5731582 West Mar 1998 A
5735844 Anderson et al. Apr 1998 A
5755753 Knowlton May 1998 A
5769880 Truckai et al. Jun 1998 A
5810801 Anderson et al. Sep 1998 A
5814008 Chen et al. Sep 1998 A
5824023 Anderson Oct 1998 A
5836999 Eckhouse et al. Nov 1998 A
5843078 Sharkey Dec 1998 A
5843143 Whitehurst Dec 1998 A
5846252 Mehl, Sr. Dec 1998 A
5868744 Willmen Feb 1999 A
5871469 Eggers et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5888198 Eggers et al. Mar 1999 A
5919219 Knowlton Jul 1999 A
5935143 Hood Aug 1999 A
5949514 Wargon Sep 1999 A
5954710 Paolini et al. Sep 1999 A
5961543 Waldmann Oct 1999 A
5984915 Loeb et al. Nov 1999 A
5993180 Westerhof et al. Nov 1999 A
6024733 Eggers et al. Feb 2000 A
6030384 Nezhat Feb 2000 A
6053172 Hovda et al. Apr 2000 A
6056548 Neuberger et al. May 2000 A
6063108 Salansky et al. May 2000 A
6066134 Eggers et al. May 2000 A
6080127 Li et al. Jun 2000 A
6080391 Tsuchiya et al. Jun 2000 A
6081934 Stefanovsky et al. Jul 2000 A
6107326 Jori Aug 2000 A
6132701 Perez et al. Oct 2000 A
6148232 Avrahami Nov 2000 A
6159222 Yiu Dec 2000 A
6186960 Tripp et al. Feb 2001 B1
6187001 Azar et al. Feb 2001 B1
6188407 Smith et al. Feb 2001 B1
6190609 Chapman et al. Feb 2001 B1
6191110 Jaynes et al. Feb 2001 B1
6210402 Olsen et al. Apr 2001 B1
6221095 Van Zuylen et al. Apr 2001 B1
6228078 Eggers et al. May 2001 B1
6231571 Ellman et al. May 2001 B1
6231593 Meserol May 2001 B1
6251127 Biel Jun 2001 B1
6258319 Hearst et al. Jul 2001 B1
6273884 Altshuler et al. Aug 2001 B1
6277116 Utely et al. Aug 2001 B1
6280438 Eckhouse et al. Aug 2001 B1
6288498 Cheng Sep 2001 B1
6308413 Westerhof et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6325797 Stewart et al. Dec 2001 B1
6343400 Massholder et al. Feb 2002 B1
6343933 Montgomery et al. Feb 2002 B1
6352535 Lewis et al. Mar 2002 B1
6353763 George et al. Mar 2002 B1
6360116 Jackson et al. Mar 2002 B1
6381497 Knowlton Apr 2002 B1
6405090 Knowlton Jun 2002 B1
6406157 Audet Jun 2002 B1
6413255 Stern Jul 2002 B1
6413268 Hartman Jul 2002 B1
6416514 Ein-Gal Jul 2002 B1
6419674 Bowser et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6430446 Knowlton Aug 2002 B1
6433343 Cimino et al. Aug 2002 B1
6436051 Morris et al. Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6440121 Weber et al. Aug 2002 B1
6452912 Leem Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6461354 Olsen et al. Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6461567 Hearst et al. Oct 2002 B1
6462070 Hasan et al. Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6471716 Pecukonis Oct 2002 B1
6482201 Olsen et al. Nov 2002 B1
6482204 Lax et al. Nov 2002 B1
6487447 Weimann et al. Nov 2002 B1
6493940 Westerhof et al. Dec 2002 B2
6494900 Salansky et al. Dec 2002 B1
6497702 Bernaz Dec 2002 B1
6508813 Althshuler Jan 2003 B1
6511475 Altshuler et al. Jan 2003 B1
6514243 Eckhouse et al. Feb 2003 B1
6514248 Eggers et al. Feb 2003 B1
6517532 Altshuler et al. Feb 2003 B1
6533775 Rizoiu et al. Mar 2003 B1
6544259 Tsaliovich Apr 2003 B1
6544261 Ellsberry et al. Apr 2003 B2
6558653 Andersen et al. May 2003 B2
6572637 Yamazaki et al. Jun 2003 B1
6582429 Krishnan et al. Jun 2003 B2
6594905 Furst et al. Jul 2003 B2
6595990 Weinstein et al. Jul 2003 B1
6597946 Avrahami Jul 2003 B2
6602245 Thiberg Aug 2003 B1
6611706 Avrahami Aug 2003 B2
6612819 Furst et al. Sep 2003 B1
6618620 Freundlich et al. Sep 2003 B1
6620158 Ronci Sep 2003 B2
6629974 Penny et al. Oct 2003 B2
6632002 Chubb et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6637877 Hartley et al. Oct 2003 B1
6662054 Kreindel et al. Dec 2003 B2
6663620 Altshuler et al. Dec 2003 B2
6676655 McDaniel Jan 2004 B2
6702808 Kreindel Mar 2004 B1
6708060 Avrahami et al. Mar 2004 B1
6711435 Avrahami Mar 2004 B2
6719754 Underwood et al. Apr 2004 B2
6723092 Brown et al. Apr 2004 B2
D490156 Fischer et al. May 2004 S
D490526 Jonsen May 2004 S
6740079 Eggers et al. May 2004 B1
6743211 Prausnitz et al. Jun 2004 B1
6749626 Bhat et al. Jun 2004 B1
6758845 Weckwerth et al. Jul 2004 B1
6761729 Babaev Jul 2004 B2
6770069 Hobart et al. Aug 2004 B1
6773431 Eggers et al. Aug 2004 B2
6780838 Lipton et al. Aug 2004 B2
6795728 Chornenky et al. Sep 2004 B2
RE38634 Westerhof et al. Oct 2004 E
6887260 McDaniel May 2005 B1
6889090 Kreindel May 2005 B2
6893435 Goble May 2005 B2
6905496 Ellman et al. Jun 2005 B1
6918907 Kelly et al. Jul 2005 B2
6974450 Weber et al. Dec 2005 B2
6997923 Anderson et al. Feb 2006 B2
7006874 Knowlton et al. Feb 2006 B2
7013179 Carter et al. Mar 2006 B2
7022121 Stern et al. Apr 2006 B2
7077840 Altshuler et al. Jul 2006 B2
7115123 Knowlton et al. Oct 2006 B2
7115124 Xiao Oct 2006 B1
7118563 Weckwerth et al. Oct 2006 B2
7141049 Stern et al. Nov 2006 B2
7153298 Cohen Dec 2006 B1
7164942 Avrahami et al. Jan 2007 B2
7204832 Altshuler et al. Apr 2007 B2
7234239 Saito et al. Jun 2007 B2
7238183 Kreindel Jul 2007 B2
7266414 Cornelius et al. Sep 2007 B2
7275819 Bleau Oct 2007 B2
7278991 Morris et al. Oct 2007 B2
7278993 Kelly et al. Oct 2007 B2
7416550 Protsenko et al. Aug 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7494488 Weber Feb 2009 B2
7517344 Van Hal et al. Apr 2009 B2
7601149 DiCarlo et al. Oct 2009 B2
7713266 Elkins et al. May 2010 B2
7771419 Carmel et al. Aug 2010 B2
7824394 Manstein Nov 2010 B2
7935107 Altshuler et al. May 2011 B2
7963985 Minamoto et al. Jun 2011 B2
8021360 Dunning et al. Sep 2011 B2
8034052 Podhajsky Oct 2011 B2
8109927 Kelly et al. Feb 2012 B2
8128622 Podhajsky et al. Mar 2012 B2
8133216 Knopp et al. Mar 2012 B2
8135475 Kreindel et al. Mar 2012 B2
8157807 Ferren et al. Apr 2012 B2
8202268 Wells et al. Jun 2012 B1
8206381 Lischinsky et al. Jun 2012 B2
8216215 Flyash et al. Jul 2012 B2
8235989 Palanker et al. Aug 2012 B2
8292882 Danek et al. Oct 2012 B2
8506564 Long et al. Aug 2013 B2
20010007068 Ota et al. Jul 2001 A1
20020035363 Edwards et al. Mar 2002 A1
20020058936 Avrahami et al. May 2002 A1
20020104543 Hollander et al. Aug 2002 A1
20020120256 Furuno et al. Aug 2002 A1
20020120260 Morris et al. Aug 2002 A1
20020120261 Morris et al. Aug 2002 A1
20020128641 Underwood et al. Sep 2002 A1
20020128648 Weber et al. Sep 2002 A1
20020143373 Courtnage et al. Oct 2002 A1
20020147384 Uchikubo Oct 2002 A1
20020173780 Altshuler et al. Nov 2002 A1
20020183245 Hasan et al. Dec 2002 A1
20020190337 House et al. Dec 2002 A1
20020198575 Sullivan Dec 2002 A1
20030004499 McDaniel Jan 2003 A1
20030032900 Ella Feb 2003 A1
20030032950 Altshuler et al. Feb 2003 A1
20030055413 Altshuler et al. Mar 2003 A1
20030055414 Altshuler et al. Mar 2003 A1
20030097162 Kreindel May 2003 A1
20030109871 Johnson et al. Jun 2003 A1
20030135250 Lauman et al. Jul 2003 A1
20030139790 Ingle et al. Jul 2003 A1
20030195494 Altshuler et al. Oct 2003 A1
20030199863 Swanson et al. Oct 2003 A1
20030199946 Gutwein Oct 2003 A1
20030216719 Debenedictis et al. Nov 2003 A1
20040010250 Manna et al. Jan 2004 A1
20040010298 Altshuler et al. Jan 2004 A1
20040015161 Lovewell Jan 2004 A1
20040015162 McGaffigan Jan 2004 A1
20040064167 Berry et al. Apr 2004 A1
20040133251 Altshuler et al. Jul 2004 A1
20040143308 Lundahl et al. Jul 2004 A1
20040147984 Altshuler et al. Jul 2004 A1
20040167501 Island et al. Aug 2004 A1
20040181216 Kelly et al. Sep 2004 A1
20040186466 Chornenky Sep 2004 A1
20040193234 Butler Sep 2004 A1
20040210214 Knowlton Oct 2004 A1
20040236320 Protsenko et al. Nov 2004 A1
20040260210 Ella et al. Dec 2004 A1
20040267252 Washington et al. Dec 2004 A1
20050015042 Sun et al. Jan 2005 A1
20050033286 Eggers et al. Feb 2005 A1
20050043653 Trimmer et al. Feb 2005 A1
20050049543 Anderson et al. Mar 2005 A1
20050075573 Park et al. Apr 2005 A1
20050085804 McGaffigan Apr 2005 A1
20050096646 Wellman et al. May 2005 A1
20050137654 Hoenig et al. Jun 2005 A1
20050137655 MacFarland et al. Jun 2005 A1
20050143793 Korman et al. Jun 2005 A1
20050147137 Slatkine Jul 2005 A1
20050149012 Penny et al. Jul 2005 A1
20050177139 Yamazaki et al. Aug 2005 A1
20050288680 Ingle et al. Dec 2005 A1
20060009763 Goble et al. Jan 2006 A1
20060036300 Kreindel Feb 2006 A1
20060047281 Kreindel Mar 2006 A1
20060095096 DeBenedictis et al. May 2006 A1
20060149343 Altshuler et al. Jul 2006 A1
20060184024 Da Silva et al. Aug 2006 A1
20060200213 McDaniel Sep 2006 A1
20060206173 Gertner et al. Sep 2006 A1
20060224217 Burgmann et al. Oct 2006 A1
20060231568 Lynn et al. Oct 2006 A1
20060247741 Hsu et al. Nov 2006 A1
20060253112 Suarez et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20060271028 Altshuler et al. Nov 2006 A1
20070016117 Sliwa et al. Jan 2007 A1
20070038206 Altshuler et al. Feb 2007 A1
20070093798 Debenedictis et al. Apr 2007 A1
20070106349 Karni et al. May 2007 A1
20070129711 Altshuler et al. Jun 2007 A1
20070129771 Kurtz et al. Jun 2007 A1
20070142881 Hennings Jun 2007 A1
20070191821 Boxer Wachler Aug 2007 A1
20070191827 Lischinsky et al. Aug 2007 A1
20070197895 Nycz et al. Aug 2007 A1
20070198004 Altshuler et al. Aug 2007 A1
20070206275 Hemmer et al. Sep 2007 A1
20070213696 Altshuler et al. Sep 2007 A1
20070239142 Altshuler et al. Oct 2007 A1
20070239143 Altshuler et al. Oct 2007 A1
20070239152 Trezon Oct 2007 A1
20070264626 DeBenedictis et al. Nov 2007 A1
20070271714 Adam et al. Nov 2007 A1
20080051680 Luebcke Feb 2008 A1
20080071334 Hoenig et al. Mar 2008 A1
20080082090 Manstein Apr 2008 A1
20080123238 Campos et al. May 2008 A1
20080125658 Lee et al. May 2008 A1
20080139901 Altshuler et al. Jun 2008 A1
20080154247 Dallarosa et al. Jun 2008 A1
20080183167 Britva et al. Jul 2008 A1
20080188846 Palanker et al. Aug 2008 A1
20080200910 Burger et al. Aug 2008 A1
20080214988 Altshuler et al. Sep 2008 A1
20080215124 Wagenaar et al. Sep 2008 A1
20080221504 Aghion Sep 2008 A1
20080294153 Allshuler et al. Nov 2008 A1
20080306476 Hennings et al. Dec 2008 A1
20090036953 Gustavsson Feb 2009 A1
20090043293 Pankratov et al. Feb 2009 A1
20090054743 Stewart Feb 2009 A1
20090105706 Livneh Apr 2009 A1
20090112205 McGill et al. Apr 2009 A1
20090119834 Kneale et al. May 2009 A1
20090171341 Pope et al. Jul 2009 A1
20090182315 Zigan et al. Jul 2009 A1
20090192503 Epshtein et al. Jul 2009 A1
20090222023 Boone et al. Sep 2009 A1
20090234341 Roth Sep 2009 A1
20090234342 Ely et al. Sep 2009 A1
20090240310 Kennedy Sep 2009 A1
20090299361 Flyash et al. Dec 2009 A1
20100010480 Mehta et al. Jan 2010 A1
20100063565 Beerwerth et al. Mar 2010 A1
20100145321 Altshuler et al. Jun 2010 A1
20100185193 Kreindel Jul 2010 A1
20100185194 Kreindel Jul 2010 A1
20100198134 Eckhouse Aug 2010 A1
20100211055 Eckhouse et al. Aug 2010 A1
20100249772 Mehta et al. Sep 2010 A1
20100274329 Bradley et al. Oct 2010 A1
20110112405 Barthe et al. May 2011 A1
20110137386 Kreindel Jun 2011 A1
20110166559 Eckhouse et al. Jul 2011 A1
20110196363 Kreindel Aug 2011 A1
20120016354 Epshtein et al. Jan 2012 A9
20120022512 Vaynberg Jan 2012 A1
20120022518 Levinson Jan 2012 A1
20120123397 Epshtein et al. May 2012 A1
20120143178 Mehta Jun 2012 A9
20120143270 Mehta Jun 2012 A1
20120197242 Rosenberg Aug 2012 A1
20120290023 Boyden et al. Nov 2012 A1
20130144280 Eckhouse et al. Jun 2013 A1
20130289679 Eckhouse et al. Oct 2013 A1
Foreign Referenced Citations (24)
Number Date Country
2495005 Feb 2004 CA
1078383 Nov 1993 CN
0528055 Feb 1993 EP
0569670 Nov 1993 EP
0743029 Jul 2002 EP
0824019 Nov 2002 EP
1852060 Nov 2007 EP
2125986 Aug 1982 GB
2202442 Sep 1988 GB
04299998 Oct 1992 JP
06113920 Apr 1994 JP
11132843 Dec 1999 JP
2003034630 Feb 2003 JP
WO-8302389 Jul 1983 WO
WO-9321992 Nov 1993 WO
WO-9909143 Feb 1999 WO
WO-9909143 Feb 1999 WO
WO-9934867 Jul 1999 WO
WO-02078644 Oct 2002 WO
WO-02078644 Oct 2002 WO
WO-02094116 Nov 2002 WO
WO-03039367 May 2003 WO
WO-03039367 May 2003 WO
WO-2006128034 Nov 2006 WO
Non-Patent Literature Citations (87)
Entry
Acne Clearance, LHE Clinical Casebook, Radiancy: Lighting the Future of Skin Care, © 2002.
Acne Star web page, describing “How to use get rid of Acne Treatment”, printed May 5, 2005.
Acne Star web page, describing Clinical Studies, “The Treatment of acne vulgaris with a novel device that uses Gallium—Nitride diode light”, printed May 5, 2005.
Aesthetic Buyers Guide: The Leading Cosmetic Practice Resource, Jan./Feb. 2004, vol. 7, No. I.
Bollen, CM. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. A pilot study: long-tenn microbiological observations”, J Clin Periodontol Oct. 1996;23(10):960-70 (Abstract).
Bollen, CM. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. A pilot study: long-term microbiological observations”. J Clin Periodontol Oct. 1996;23(10):960-70 (Abstract).
Bollen, CM. et al., The effect of a one-stage full-mouth disinfection on different intra-0ral niches. Clinical and microbiological observations•. J Clin Periodontol Jan. 1998;25(1 ):56-66 (Abstract).
Bollen, CM. et al., “The effect of a one-stage full-mouth disinfection on different intra-oral niches. Clinical and microbiological observations”, J Clin Periodontol Jan. 1998;25(1 ):56-66 (Abstract).
Calderhead, R. Glen, “The Photobiology of LED Phototherapy”.
Calderl-Iead, R. Glen, “The Photobiology of LED Phototherapy”.
Charakida et al., “Phototherapy in the Treatment of Acne Vulgaris, What is the Role?”, Am. J. Clin. Dermatol 2004: 5(4): 211-216.
Cohen L.R., “What causes bad breath?”, University of Toronto; webpage (printed before Nov. 2, 2004).
Cohen Lr., “What causes bad breath?”, University of Toronto; webpage (printed before Nov. 2, 2004).
Coventry et al. (2000) “ABC of oral health: Periodontal disease” British Medical Journal, 321, 36-39.
De Soete, M. et al .. One-stage full-mouth disinfection. Long-term microbiological results analyzed by checker board DNA-DNA hybridization•, J Periodontol Mar. 2001; 72(3):374-82 (Abstract).
De Soete, M. et al., “One-stage full-mouth disinfection. Long-term microbiological results analyzed by checker board DNA-DNA hybridization”, J Periodontol Mar. 2001; 72(3):374-82 (Abstract).
Elman M. et al., “The effective treatment of acne vulgaris by a high-intensity, narrow bank 405-420 nm light source”, Cosmetic & Laser Ther 2003; 5: 111-116.
Elman M. et al., The effective treatment of acne vulgaris by a high-intensity, narrow bank 405-420 nm light source•, Cosmetic & Laser Ther 2003; 5: 111-116.
Flow Control Network web page, “Mini Diaphragm Pumps for Precision Dispensing” by Ping Lin, printed Aug. 2, 2005.
Friedberg J.S. et al., “Antibody-Targeted Photolysis Bacteriocidal Effects of Sn (IV) Chlorin e6-0extran-Monoclonal Antibody Conjugates”, Annals New York Academy of Sciences 618:383-393, 1991.
Friedberg JS et al., “Antibody-Targeted Photolysis Bacteriocidal Effects of Sn (IV) Chlonn e6-Dextran-Monoclonal Antibody Conjugates”, Annals New York Academy of Sciences 618:383-393, 1991.
Greenstein G., Full-mouth therapy versus individual quadrant root planning: a critical commentary, J Periodontol Jul. 2002;73(7):797-812 (Abstract).
Greenstein G., Full-mouth therapy versus individual quadrant root planning: a critical commentary, JPeriodontol Jul. 2002;73(7):797-812 (Abstract).
Guidelines for Limiting Exposure to Time-Varying Electric, Magnetic, and Magnetic Fields (Up to 300 GHz), International Commission on Non-Ionizing Radiation Protection, ICNIRP Guidelines, Apr. 1998, vol. 7 4, No. 4, pp. 494-522.
Hamblin, M. et al., “Rapid Control of Wound Infections by Targeted Photodynamic Therapy Monitored by In Vivo Bioluminescence Imagining”, Photochemistry and Photobiology, 2002, 75(1 ): 51-57.
Hamblin, M. et al., Rapid Control of Wound Infections by Targeted Photodynamic Therapy Monitored by In Vivo Biluminescence Imagining•, Photochemistry and Photobiology, 2002, 75(1): 51-57.
Komerik et al. (2003) “In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated photosensitization in an animal model” Antimicrobial Agents and Chemotherapy, 47(3), 932-940.
Krespi, et al. (2005) “Lethal photosensitization of oral pathogens via red-filtered halogen lamp” Oral Diseases, 11(S1), 92-95.
Krespi, et al. (2005) “Lethal photosensitization of oral pathogens via red-filtered halogen larnp” Oral Diseases, 11(S1 ), 92-95.
Malik, Z. et al., “New Trends in Photobiology (Invited Review) Bactericidal Effects of Photoactivated Porphyrins—An Alternative Approach to Antimicrobial Drugs”, Journal of Photochemistry and Photobiology, B: Biology, May 1, 1990}—281-293.
Malik, Z. et al., “New Trends in Photobiology (Invited Review) Bactericidal Effects of Photoactivated Porphyrins • An Alternative Approach to Antimicrobial Drugs”, Journal of Photochemistry and Photobiology, B: Biology, 5 J.19901—281-293.
Matevski D. et al., “Lethal photosensitization of periodontal pathogens by a red-filtered Xenon lamp in invitro”, J. Periodont. Res. 2003; 38:428-435.
Matevski D. et al., “Lethal photosensitization of periodontal pathogens by a red-filtered Xenon lamp in invitro”, JPeriodont. Res. 2003. 38:428-435.
Matevski D. et al., Sensitivity of Porphyromonas gingivalis to Light-Activated Toluidine Blue o•. University of Toronto, Faculty of Dentistry; Slide presentation (presented before Nov. 15, 2002).
Matevski D. et al., “Sensitivity of Porphyromonas gingivalis to Light-Activated Toluidine Blue O”, University of Toronto, Faculty of Dentistry; Slide presentation (presented before Nov. 15, 2002).
Meisel et al. (2005) Photodynamic therapy for periodontal diseases: State of the are• J. Photochem. Photobiol., 79, 159-170.
Meisel etal. (2005) “Photodynamic therapy for periodontal diseases: State of the are” J. Photochem. Photobiol., 79, 159-170.
Mongardini, C. et al., One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized ear l y-0nset periodontitis. I. Long-tenn clinical observations•, J Periodontol Jun. 1999;70(6):632-45 —[Abstrac!)—.
Mongardini, C. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. I. Long-term clinical observations”, J Periodontol Jun. 1999;70(6):632-45 1Abstrac!2.—.
Morton C.A. et al., An open study to determine the efficacy of blue light in the treatment of mild to moderate acne: preliminary data (publication status unknown).
Nakano et al. (2002) “Correlation between oral malodor and periodontal bacteria” Microbes Infect., 4(6), 679-683.
Nakano et al. (2002) “Correlation between oral malodor and periodontal bacteria” Microbes Infect., 4(6). 679-683.
Ondine Biopharma web page—printed Oct. 15, 2002.
Papageorgiou et al., “Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris”, British Journal of Dermatology 2000: 142: 973-978.
Pharmaceutical description, Levulan® Kerastick arninolevulinic acid I-IC!) for Topical Solution, 20′X.
Pharmaceutical description, Levulan® Kerastick •aminolevulinic acid HCI) for Topical Solution, 20%.
Quirynen, M. et al. Fuli- vs. partial-mouth disinfection in the treatment of periodontal infections: short-tennclinical and microbiological observations•. J Dent Res Aug. 1995;74(8):1459-67 (Abstract).
Quirynen, M. et al. “Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations”, J Dent Res Aug. 1995;74(8):1459-67 (Abstract).
Quirynen, M. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized ear l y-onset periodontitis. II. Long-term impact on microbial load”, J Periodontol Jun. 1999;70(6):646-56 (Abstract).
Quirynen, M. et al., “The effect of a 1-stage full-mouth disinfection on oral malodor and microbial colonization of the tongue in periodontitis. A pilot study”, J Periodontol Mar. 1998;69(3):374-82 (Abstract).
Quirynen, M. et al., “The intra-oral translocation of periodontopathogens jeopardises the outcome of periodontal therapy”, Journal of Clinical Periodontology, Jun. 2001, vol. 28, Issue 6, p. 499 (Abstract).
Quirynen, M. et al., The role of chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adults periodontitis. Long-term clinical and microbiological observations•. J Clin Periodontol 2000 A1.IQ;27.{fil:579-89 J—Abstrac!)—.
Quirynen, M. et al., “The role of chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adult periodontitis. Long-term clinical and microbiological observations”, J Clin Periodontol 2000 A1!JL2˜579-89 J—Abstrac—!).
Quirynen. M. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. II. Long-term impact on microbial load”, J Peridontol Jun. 1999;70(6):646-56 J—Abstrac!2.—.
Sanz et al. (2001) “Fundamentals of breath malodour” Journal of Contemporary Dental Practice, 2(4 ), 1-13.
Sanz et al. (2001) “Fundamentals of breath malodour” Journal of Contemporary Dental Practice, 2(4), 1-13.
Sarkar et al. (1993) “Lethal photosensitization of bacteria in subgingival plaque from patients with chronic periodontitis” J. Periodont. Res , 28, 204-21 O.
Sarkar et al. (1993) “Lethal photosensitization of bacteria in subgingival plaque from patients with chronic periodontitis” J. Periodont. Res., 28, 204-210.
Search results from Delphion web site, dated Nov. 22, 2005.
Skin91 I .com web page regarding Peter Thomas Roth Clinical Acne Medication, acne treatment-Benzoyl Peroxide 5% pbp5, printed Aug. 19, 2005.
Skin91 I .corn web page regarding Peter Thomas Roth Clinical Acne Medication, acne treatment-Benzoyl Peroxide 5% pbp5, printed Apr. 19, 2005.
Soukos et al. (1998) “Targeted antimicrobial photochemotherapy”, Antimicrobial Agents and Chemotherapy 42( 10 ), 2595-2601.
Soukos et al. (1998) “Targeted antimicrobial photochemotherapy”, Antimicrobial Agents and Chemotherapy 42(10), 2595-2601.
Spire Awarded Contract for Ear Surgery Laser—Press Release Aug. 23, 2002.
Temperatures.com web page, “Thermistor Temperature Sensors,” printed Aug. 2, 200.
Temperatures.corn web page, “Thermistor Temperature Sensors,” printed Aug. 2, 200.
Vandekerckhove, BN. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. Long-term clinical observations of a pilot study”, J Periodontol Dec. 1996;67(12):1251-9 (Abstract).
Vandekerckhove, BN. et al.. “Full- versus partial-mouth disinfection in the treatment of periodontal infections. Long-term clinical observations of a pilot study”, J Periodontal Dec. 1996;67(12):1251-9 (Abstract).
Wainwright M., Photodynamic antimicrobial chemotherapy (PACT), Journal of Antimicrobial Chemotherapy (1998) 42, 13-28.
Wilson (2005) “Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infection” Photochem. Photobiol. Sci . . . 3, 412-418.
Wilson (2005) “Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infection” Photochem. Photobiol. Sci., 3, 412-418.
Wilson et al. (1995) “Bacteria in supragingival plaque samples can be killed by low-power laser light in the presence of a photosensitizer” J. Appl. Bacteriol . . . 78, 569-574.
Wilson et al. (1995) “Bacteria in supragingival plaque samples can be killed by low-power laser light in the presence of a photsensitizer” J. Appl. Bacteriol., 78, 569-574.
Wood, et al. (1999) “An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biofilms formed in vivo” J. Photochem. Photogiol. B: Biol . . . 50, 1-7.
Wood, et al. (1999) “An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biofilrns formed in vivo” J. Photochem. Photogiol. B: Biol., 50, 1-7.
www.lightbioscience.com web page, Gentle Waves Cosmcceuticals, printed Jul. 29, 200.
www.lightbioscience.com web page, Gentle Waves LED Photomodulation Fact Sheet, printed Jul. 29, 2005.
www.lightbioscience.com web page, GentleWaves Cosmeceuticals, printed Jul. 29, 200.
www.lightbioscience.com web page, GentleWaves LED Photomodulation Fact Sheet, printed Jul. 29, 2005.
Guidelines for Limiting Exposure to Time-Varying Electric, Magnetic, and Electromagnetic Fields (Up to 300 GHz), International Commission on Non-Ionizing Radiation Protection, ICNIRP Guidelines, Apr. 1998, vol. 74, No. 4, pp. 496-522.
PCT/IL11/00256 International Search Report.
PCT/IL11/00170 International Search Report.
PCT/IL10/00751 International Search Report.
PCT/IL10/00557 International Search Report.
PCT/IL10/00173 International Search Report.
PCT/IL09/00693 International Search Report.
PCT/IL09/00033 International Search Report.
Related Publications (1)
Number Date Country
20120041431 A1 Feb 2012 US
Provisional Applications (1)
Number Date Country
61208621 Feb 2009 US